ResearcherFirst Affiliated Hospital of Wenzhou Medical UniversityActive in the last 2 years
Fugen Shangguan
Matched on ORCID iD 0000-0001-7355-562X; OpenAlex author ID A5063789627. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper
Papers 4
- Fucoxanthin suppresses pancreatic cancer progression by inducing bioenergetics metabolism crisis and promoting SLC31A1‑mediated sensitivity to DDP. Co-author DOI 10.3892/ijo.2025.5737↗
- Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenocarcinoma via targeting SLC1A5. Co-author DOI 10.1002/jbt.23192↗
- 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Caspase-dependent cell death in pancreatic… First author DOI 10.1016/j.phymed.2022.154164↗
- RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues. Co-author DOI 10.18632/aging.203589↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Guihua Jin · 3 shared papers, 2021–2022 · strength 0.48
- Paper RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocar… DOI 10.18632/aging.203589↗
- Paper Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenoc… DOI 10.1002/jbt.23192↗
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164↗
- Linhua Lan · 3 shared papers, 2021–2022 · strength 0.48
- Paper RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocar… DOI 10.18632/aging.203589↗
- Paper Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenoc… DOI 10.1002/jbt.23192↗
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164↗
- Nengfang Ma · 2 shared papers, 2022–2025 · strength 0.41
- Paper Fucoxanthin suppresses pancreatic cancer progression by inducing bioenergetics metabolism crisis and promoting SLC31A1‑… DOI 10.3892/ijo.2025.5737↗
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164↗
- Hailong Yang · 2 shared papers, 2022–2025 · strength 0.41
- Paper Fucoxanthin suppresses pancreatic cancer progression by inducing bioenergetics metabolism crisis and promoting SLC31A1‑… DOI 10.3892/ijo.2025.5737↗
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164↗
- Shijia Wu · 2 shared papers, 2022 · strength 0.29
- Paper Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenoc… DOI 10.1002/jbt.23192↗
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164↗
- Huimin Huang · 2 shared papers, 2022 · strength 0.29
- Paper Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenoc… DOI 10.1002/jbt.23192↗
- Paper 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Ca… DOI 10.1016/j.phymed.2022.154164↗
- Qingqing Ruan · 1 shared paper, 2021 · strength 0.19
- Hongbao Yang · 1 shared paper, 2022 · strength 0.15
- Percy David Papa Akuetteh · 1 shared paper, 2022 · strength 0.15
- Qiyu Zhang · 1 shared paper, 2022 · strength 0.15
- Hongping Xia · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.